nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—CA5A—Reversible hydration of carbon dioxide—CA1—esophageal cancer	0.0428	0.0681	CbGpPWpGaD
Metolazone—CA7—Reversible hydration of carbon dioxide—CA1—esophageal cancer	0.04	0.0636	CbGpPWpGaD
Metolazone—CA5B—Reversible hydration of carbon dioxide—CA1—esophageal cancer	0.04	0.0636	CbGpPWpGaD
Metolazone—CA5A—Reversible hydration of carbon dioxide—CA2—esophageal cancer	0.0391	0.0623	CbGpPWpGaD
Metolazone—CA4—Erythrocytes take up carbon dioxide and release oxygen—CA1—esophageal cancer	0.0372	0.0592	CbGpPWpGaD
Metolazone—CA12—Reversible hydration of carbon dioxide—CA1—esophageal cancer	0.037	0.0589	CbGpPWpGaD
Metolazone—CA7—Reversible hydration of carbon dioxide—CA2—esophageal cancer	0.0365	0.0582	CbGpPWpGaD
Metolazone—CA5B—Reversible hydration of carbon dioxide—CA2—esophageal cancer	0.0365	0.0582	CbGpPWpGaD
Metolazone—CA4—Erythrocytes take up carbon dioxide and release oxygen—CA2—esophageal cancer	0.034	0.0541	CbGpPWpGaD
Metolazone—CA12—Reversible hydration of carbon dioxide—CA2—esophageal cancer	0.0339	0.0539	CbGpPWpGaD
Metolazone—CA4—Reversible hydration of carbon dioxide—CA1—esophageal cancer	0.0295	0.047	CbGpPWpGaD
Metolazone—CA4—Reversible hydration of carbon dioxide—CA2—esophageal cancer	0.027	0.043	CbGpPWpGaD
Metolazone—Venous thrombosis—Carboplatin—esophageal cancer	0.0257	0.0816	CcSEcCtD
Metolazone—CA9—Reversible hydration of carbon dioxide—CA1—esophageal cancer	0.0239	0.038	CbGpPWpGaD
Metolazone—CA9—Reversible hydration of carbon dioxide—CA2—esophageal cancer	0.0218	0.0347	CbGpPWpGaD
Metolazone—Skin necrosis—Cisplatin—esophageal cancer	0.0116	0.037	CcSEcCtD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—HIF1A—esophageal cancer	0.00805	0.0128	CbGpPWpGaD
Metolazone—Venous thrombosis—Cisplatin—esophageal cancer	0.00752	0.0239	CcSEcCtD
Metolazone—Hypophosphataemia—Cisplatin—esophageal cancer	0.00699	0.0222	CcSEcCtD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—CREBBP—esophageal cancer	0.00658	0.0105	CbGpPWpGaD
Metolazone—Skin necrosis—Methotrexate—esophageal cancer	0.00638	0.0203	CcSEcCtD
Metolazone—Peripheral coldness—Capecitabine—esophageal cancer	0.00629	0.02	CcSEcCtD
Metolazone—Venous thrombosis—Capecitabine—esophageal cancer	0.00555	0.0176	CcSEcCtD
Metolazone—Quinethazone—CA1—esophageal cancer	0.00504	0.114	CrCbGaD
Metolazone—Methyclothiazide—CA1—esophageal cancer	0.00483	0.109	CrCbGaD
Metolazone—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00471	0.015	CcSEcCtD
Metolazone—Benzthiazide—CA1—esophageal cancer	0.00469	0.106	CrCbGaD
Metolazone—Chlorothiazide—CA1—esophageal cancer	0.00465	0.105	CrCbGaD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EP300—esophageal cancer	0.00448	0.00713	CbGpPWpGaD
Metolazone—Hyperuricaemia—Cisplatin—esophageal cancer	0.00438	0.0139	CcSEcCtD
Metolazone—Hypercalcaemia—Capecitabine—esophageal cancer	0.00431	0.0137	CcSEcCtD
Metolazone—Pain—Carboplatin—esophageal cancer	0.00422	0.0134	CcSEcCtD
Metolazone—Throat sore—Capecitabine—esophageal cancer	0.00415	0.0132	CcSEcCtD
Metolazone—Blood uric acid increased—Cisplatin—esophageal cancer	0.00414	0.0132	CcSEcCtD
Metolazone—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00412	0.0131	CcSEcCtD
Metolazone—Chlorthalidone—CA1—esophageal cancer	0.004	0.0903	CrCbGaD
Metolazone—Skin exfoliation—Cisplatin—esophageal cancer	0.00388	0.0123	CcSEcCtD
Metolazone—Quinethazone—CA2—esophageal cancer	0.00382	0.0862	CrCbGaD
Metolazone—Neuropathy—Cisplatin—esophageal cancer	0.00381	0.0121	CcSEcCtD
Metolazone—Methyclothiazide—CA2—esophageal cancer	0.00366	0.0826	CrCbGaD
Metolazone—Petechiae—Capecitabine—esophageal cancer	0.00364	0.0116	CcSEcCtD
Metolazone—CA9—Cellular response to hypoxia—HIF1A—esophageal cancer	0.00356	0.00566	CbGpPWpGaD
Metolazone—Benzthiazide—CA2—esophageal cancer	0.00355	0.0801	CrCbGaD
Metolazone—Chlorothiazide—CA2—esophageal cancer	0.00352	0.0795	CrCbGaD
Metolazone—Indapamide—CA2—esophageal cancer	0.00352	0.0795	CrCbGaD
Metolazone—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00329	0.0105	CcSEcCtD
Metolazone—Nocturia—Capecitabine—esophageal cancer	0.00323	0.0103	CcSEcCtD
Metolazone—Chlorthalidone—CA2—esophageal cancer	0.00303	0.0684	CrCbGaD
Metolazone—Hyponatraemia—Cisplatin—esophageal cancer	0.00296	0.00942	CcSEcCtD
Metolazone—CA9—Cellular response to hypoxia—CREBBP—esophageal cancer	0.00291	0.00463	CbGpPWpGaD
Metolazone—Skin exfoliation—Capecitabine—esophageal cancer	0.00286	0.00909	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.00286	0.00455	CbGpPWpGaD
Metolazone—Neuropathy—Capecitabine—esophageal cancer	0.00281	0.00894	CcSEcCtD
Metolazone—Petechiae—Methotrexate—esophageal cancer	0.00271	0.00862	CcSEcCtD
Metolazone—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00269	0.00857	CcSEcCtD
Metolazone—Hypokalaemia—Cisplatin—esophageal cancer	0.00268	0.00854	CcSEcCtD
Metolazone—Cramp muscle—Cisplatin—esophageal cancer	0.00265	0.00845	CcSEcCtD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.0026	0.00415	CbGpPWpGaD
Metolazone—Pancreatitis—Cisplatin—esophageal cancer	0.0025	0.00795	CcSEcCtD
Metolazone—Photosensitivity—Capecitabine—esophageal cancer	0.00247	0.00788	CcSEcCtD
Metolazone—Swelling—Capecitabine—esophageal cancer	0.00246	0.00784	CcSEcCtD
Metolazone—Abdominal discomfort—Cisplatin—esophageal cancer	0.00244	0.00777	CcSEcCtD
Metolazone—Vascular purpura—Capecitabine—esophageal cancer	0.00243	0.00773	CcSEcCtD
Metolazone—Hyperuricaemia—Methotrexate—esophageal cancer	0.0024	0.00764	CcSEcCtD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00238	0.00379	CbGpPWpGaD
Metolazone—Blood uric acid increased—Methotrexate—esophageal cancer	0.00227	0.00722	CcSEcCtD
Metolazone—Purpura—Capecitabine—esophageal cancer	0.00225	0.00717	CcSEcCtD
Metolazone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00223	0.00709	CcSEcCtD
Metolazone—Lethargy—Capecitabine—esophageal cancer	0.00222	0.00706	CcSEcCtD
Metolazone—Hyponatraemia—Capecitabine—esophageal cancer	0.00218	0.00694	CcSEcCtD
Metolazone—Skin exfoliation—Methotrexate—esophageal cancer	0.00213	0.00677	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	0.00208	0.00332	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—PRDX2—esophageal cancer	0.00201	0.0032	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—PRDX1—esophageal cancer	0.00201	0.0032	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	0.002	0.00318	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—ABCB1—esophageal cancer	0.002	0.00318	CbGpPWpGaD
Metolazone—Dry skin—Capecitabine—esophageal cancer	0.00199	0.00634	CcSEcCtD
Metolazone—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00198	0.00632	CcSEcCtD
Metolazone—CA9—Cellular response to hypoxia—EP300—esophageal cancer	0.00198	0.00315	CbGpPWpGaD
Metolazone—Hypokalaemia—Capecitabine—esophageal cancer	0.00198	0.00629	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00196	0.00623	CcSEcCtD
Metolazone—Tinnitus—Cisplatin—esophageal cancer	0.0019	0.00605	CcSEcCtD
Metolazone—Abdominal distension—Capecitabine—esophageal cancer	0.00189	0.00602	CcSEcCtD
Metolazone—Photosensitivity—Methotrexate—esophageal cancer	0.00184	0.00586	CcSEcCtD
Metolazone—Abdominal discomfort—Capecitabine—esophageal cancer	0.0018	0.00573	CcSEcCtD
Metolazone—CA7—trachea—esophageal cancer	0.00175	0.131	CbGeAlD
Metolazone—Flatulence—Cisplatin—esophageal cancer	0.00175	0.00557	CcSEcCtD
Metolazone—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00171	0.00546	CcSEcCtD
Metolazone—Muscle spasms—Cisplatin—esophageal cancer	0.00171	0.00543	CcSEcCtD
Metolazone—Hyperglycaemia—Capecitabine—esophageal cancer	0.00169	0.00539	CcSEcCtD
Metolazone—Vision blurred—Cisplatin—esophageal cancer	0.00167	0.00532	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00166	0.00528	CcSEcCtD
Metolazone—Lethargy—Methotrexate—esophageal cancer	0.00165	0.00525	CcSEcCtD
Metolazone—Ill-defined disorder—Cisplatin—esophageal cancer	0.00165	0.00524	CcSEcCtD
Metolazone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00164	0.00522	CcSEcCtD
Metolazone—Anaemia—Cisplatin—esophageal cancer	0.00164	0.00522	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	0.00164	0.0026	CbGpPWpGaD
Metolazone—Malaise—Cisplatin—esophageal cancer	0.0016	0.00509	CcSEcCtD
Metolazone—Leukopenia—Cisplatin—esophageal cancer	0.00159	0.00506	CcSEcCtD
Metolazone—Epistaxis—Capecitabine—esophageal cancer	0.00158	0.00503	CcSEcCtD
Metolazone—Agranulocytosis—Capecitabine—esophageal cancer	0.00156	0.00497	CcSEcCtD
Metolazone—CA7—digestive system—esophageal cancer	0.00151	0.113	CbGeAlD
Metolazone—Anxiety—Cisplatin—esophageal cancer	0.00151	0.00479	CcSEcCtD
Metolazone—Hepatitis—Capecitabine—esophageal cancer	0.0015	0.00478	CcSEcCtD
Metolazone—Discomfort—Cisplatin—esophageal cancer	0.00149	0.00475	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.00149	0.00237	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00148	0.00236	CbGpPWpGaD
Metolazone—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00146	0.00464	CcSEcCtD
Metolazone—Erythema multiforme—Capecitabine—esophageal cancer	0.00142	0.00452	CcSEcCtD
Metolazone—Thrombocytopenia—Cisplatin—esophageal cancer	0.00142	0.00451	CcSEcCtD
Metolazone—Tinnitus—Capecitabine—esophageal cancer	0.0014	0.00446	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.0014	0.00222	CbGpPWpGaD
Metolazone—Anorexia—Cisplatin—esophageal cancer	0.00138	0.00439	CcSEcCtD
Metolazone—Pancreatitis—Methotrexate—esophageal cancer	0.00137	0.00436	CcSEcCtD
Metolazone—Chills—Capecitabine—esophageal cancer	0.00135	0.00429	CcSEcCtD
Metolazone—Abdominal discomfort—Methotrexate—esophageal cancer	0.00134	0.00427	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	0.00134	0.00213	CbGpPWpGaD
Metolazone—CA9—digestive system—esophageal cancer	0.00132	0.0993	CbGeAlD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00132	0.00211	CbGpPWpGaD
Metolazone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00132	0.0042	CcSEcCtD
Metolazone—Paraesthesia—Cisplatin—esophageal cancer	0.0013	0.00414	CcSEcCtD
Metolazone—Flatulence—Capecitabine—esophageal cancer	0.00129	0.0041	CcSEcCtD
Metolazone—Erectile dysfunction—Methotrexate—esophageal cancer	0.00129	0.0041	CcSEcCtD
Metolazone—Dysgeusia—Capecitabine—esophageal cancer	0.00128	0.00408	CcSEcCtD
Metolazone—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00128	0.00406	CcSEcCtD
Metolazone—Back pain—Capecitabine—esophageal cancer	0.00127	0.00403	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00126	0.00201	CbGpPWpGaD
Metolazone—Decreased appetite—Cisplatin—esophageal cancer	0.00126	0.00401	CcSEcCtD
Metolazone—Muscle spasms—Capecitabine—esophageal cancer	0.00126	0.004	CcSEcCtD
Metolazone—Drowsiness—Methotrexate—esophageal cancer	0.00125	0.00397	CcSEcCtD
Metolazone—Pain—Cisplatin—esophageal cancer	0.00124	0.00394	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00124	0.00393	CcSEcCtD
Metolazone—Vision blurred—Capecitabine—esophageal cancer	0.00123	0.00392	CcSEcCtD
Metolazone—SLC12A3—lung—esophageal cancer	0.00123	0.0925	CbGeAlD
Metolazone—Ill-defined disorder—Capecitabine—esophageal cancer	0.00121	0.00386	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00121	0.00193	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00121	0.00193	CbGpPWpGaD
Metolazone—Anaemia—Capecitabine—esophageal cancer	0.00121	0.00385	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—HIST1H2BM—esophageal cancer	0.0012	0.0019	CbGpPWpGaD
Metolazone—Feeling abnormal—Cisplatin—esophageal cancer	0.00119	0.0038	CcSEcCtD
Metolazone—Malaise—Capecitabine—esophageal cancer	0.00118	0.00376	CcSEcCtD
Metolazone—Epistaxis—Methotrexate—esophageal cancer	0.00118	0.00374	CcSEcCtD
Metolazone—Vertigo—Capecitabine—esophageal cancer	0.00118	0.00374	CcSEcCtD
Metolazone—Syncope—Capecitabine—esophageal cancer	0.00117	0.00373	CcSEcCtD
Metolazone—Leukopenia—Capecitabine—esophageal cancer	0.00117	0.00373	CcSEcCtD
Metolazone—CA4—neck—esophageal cancer	0.00117	0.0879	CbGeAlD
Metolazone—Agranulocytosis—Methotrexate—esophageal cancer	0.00116	0.0037	CcSEcCtD
Metolazone—Palpitations—Capecitabine—esophageal cancer	0.00116	0.00368	CcSEcCtD
Metolazone—Loss of consciousness—Capecitabine—esophageal cancer	0.00115	0.00366	CcSEcCtD
Metolazone—Cough—Capecitabine—esophageal cancer	0.00114	0.00363	CcSEcCtD
Metolazone—CA12—trachea—esophageal cancer	0.00114	0.0854	CbGeAlD
Metolazone—Hypertension—Capecitabine—esophageal cancer	0.00113	0.0036	CcSEcCtD
Metolazone—Hepatitis—Methotrexate—esophageal cancer	0.00112	0.00356	CcSEcCtD
Metolazone—Arthralgia—Capecitabine—esophageal cancer	0.00111	0.00355	CcSEcCtD
Metolazone—Chest pain—Capecitabine—esophageal cancer	0.00111	0.00355	CcSEcCtD
Metolazone—Anxiety—Capecitabine—esophageal cancer	0.00111	0.00353	CcSEcCtD
Metolazone—Discomfort—Capecitabine—esophageal cancer	0.0011	0.0035	CcSEcCtD
Metolazone—Dry mouth—Capecitabine—esophageal cancer	0.00109	0.00347	CcSEcCtD
Metolazone—Hypersensitivity—Cisplatin—esophageal cancer	0.00107	0.0034	CcSEcCtD
Metolazone—Erythema multiforme—Methotrexate—esophageal cancer	0.00106	0.00337	CcSEcCtD
Metolazone—Shock—Capecitabine—esophageal cancer	0.00105	0.00334	CcSEcCtD
Metolazone—Thrombocytopenia—Capecitabine—esophageal cancer	0.00105	0.00333	CcSEcCtD
Metolazone—Tinnitus—Methotrexate—esophageal cancer	0.00104	0.00332	CcSEcCtD
Metolazone—Asthenia—Cisplatin—esophageal cancer	0.00104	0.00331	CcSEcCtD
Metolazone—CA5A—Metabolism—BLVRB—esophageal cancer	0.00102	0.00163	CbGpPWpGaD
Metolazone—CA5A—Metabolism—SLC52A3—esophageal cancer	0.00102	0.00163	CbGpPWpGaD
Metolazone—Anorexia—Capecitabine—esophageal cancer	0.00102	0.00324	CcSEcCtD
Metolazone—Chills—Methotrexate—esophageal cancer	0.001	0.0032	CcSEcCtD
Metolazone—Diarrhoea—Cisplatin—esophageal cancer	0.000991	0.00315	CcSEcCtD
Metolazone—CA12—digestive system—esophageal cancer	0.000979	0.0735	CbGeAlD
Metolazone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000973	0.0031	CcSEcCtD
Metolazone—Insomnia—Capecitabine—esophageal cancer	0.000966	0.00307	CcSEcCtD
Metolazone—Paraesthesia—Capecitabine—esophageal cancer	0.000959	0.00305	CcSEcCtD
Metolazone—CA7—Metabolism—SLC52A3—esophageal cancer	0.000955	0.00152	CbGpPWpGaD
Metolazone—CA5B—Metabolism—BLVRB—esophageal cancer	0.000955	0.00152	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SLC52A3—esophageal cancer	0.000955	0.00152	CbGpPWpGaD
Metolazone—CA7—Metabolism—BLVRB—esophageal cancer	0.000955	0.00152	CbGpPWpGaD
Metolazone—Dysgeusia—Methotrexate—esophageal cancer	0.000954	0.00304	CcSEcCtD
Metolazone—Back pain—Methotrexate—esophageal cancer	0.000942	0.003	CcSEcCtD
Metolazone—Dyspepsia—Capecitabine—esophageal cancer	0.00094	0.00299	CcSEcCtD
Metolazone—Decreased appetite—Capecitabine—esophageal cancer	0.000928	0.00295	CcSEcCtD
Metolazone—Vomiting—Cisplatin—esophageal cancer	0.000921	0.00293	CcSEcCtD
Metolazone—Fatigue—Capecitabine—esophageal cancer	0.000921	0.00293	CcSEcCtD
Metolazone—Vision blurred—Methotrexate—esophageal cancer	0.000918	0.00292	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000917	0.00146	CbGpPWpGaD
Metolazone—Rash—Cisplatin—esophageal cancer	0.000914	0.00291	CcSEcCtD
Metolazone—Constipation—Capecitabine—esophageal cancer	0.000913	0.00291	CcSEcCtD
Metolazone—Pain—Capecitabine—esophageal cancer	0.000913	0.00291	CcSEcCtD
Metolazone—Dermatitis—Cisplatin—esophageal cancer	0.000913	0.0029	CcSEcCtD
Metolazone—CA9—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.00091	0.00145	CbGpPWpGaD
Metolazone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000904	0.00288	CcSEcCtD
Metolazone—Anaemia—Methotrexate—esophageal cancer	0.0009	0.00287	CcSEcCtD
Metolazone—CA12—Metabolism—SLC52A3—esophageal cancer	0.000885	0.00141	CbGpPWpGaD
Metolazone—CA12—Metabolism—BLVRB—esophageal cancer	0.000885	0.00141	CbGpPWpGaD
Metolazone—Feeling abnormal—Capecitabine—esophageal cancer	0.00088	0.0028	CcSEcCtD
Metolazone—Malaise—Methotrexate—esophageal cancer	0.000879	0.0028	CcSEcCtD
Metolazone—Vertigo—Methotrexate—esophageal cancer	0.000875	0.00279	CcSEcCtD
Metolazone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000873	0.00278	CcSEcCtD
Metolazone—Leukopenia—Methotrexate—esophageal cancer	0.000872	0.00277	CcSEcCtD
Metolazone—CA5A—Metabolism—SLC10A2—esophageal cancer	0.00087	0.00138	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CA1—esophageal cancer	0.00087	0.00138	CbGpPWpGaD
Metolazone—Nausea—Cisplatin—esophageal cancer	0.000861	0.00274	CcSEcCtD
Metolazone—Cough—Methotrexate—esophageal cancer	0.00085	0.00271	CcSEcCtD
Metolazone—Urticaria—Capecitabine—esophageal cancer	0.000848	0.0027	CcSEcCtD
Metolazone—Abdominal pain—Capecitabine—esophageal cancer	0.000844	0.00269	CcSEcCtD
Metolazone—SLC12A3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000832	0.00132	CbGpPWpGaD
Metolazone—Arthralgia—Methotrexate—esophageal cancer	0.000829	0.00264	CcSEcCtD
Metolazone—Chest pain—Methotrexate—esophageal cancer	0.000829	0.00264	CcSEcCtD
Metolazone—Discomfort—Methotrexate—esophageal cancer	0.000819	0.00261	CcSEcCtD
Metolazone—CA12—lung—esophageal cancer	0.000817	0.0614	CbGeAlD
Metolazone—CA5B—Metabolism—SLC10A2—esophageal cancer	0.000812	0.00129	CbGpPWpGaD
Metolazone—CA7—Metabolism—CA1—esophageal cancer	0.000812	0.00129	CbGpPWpGaD
Metolazone—CA7—Metabolism—SLC10A2—esophageal cancer	0.000812	0.00129	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CA1—esophageal cancer	0.000812	0.00129	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CA2—esophageal cancer	0.000795	0.00127	CbGpPWpGaD
Metolazone—Hypersensitivity—Capecitabine—esophageal cancer	0.000787	0.0025	CcSEcCtD
Metolazone—Thrombocytopenia—Methotrexate—esophageal cancer	0.000778	0.00248	CcSEcCtD
Metolazone—Asthenia—Capecitabine—esophageal cancer	0.000766	0.00244	CcSEcCtD
Metolazone—Anorexia—Methotrexate—esophageal cancer	0.000758	0.00241	CcSEcCtD
Metolazone—Pruritus—Capecitabine—esophageal cancer	0.000756	0.0024	CcSEcCtD
Metolazone—CA12—Metabolism—CA1—esophageal cancer	0.000752	0.0012	CbGpPWpGaD
Metolazone—CA12—Metabolism—SLC10A2—esophageal cancer	0.000752	0.0012	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CA2—esophageal cancer	0.000743	0.00118	CbGpPWpGaD
Metolazone—CA7—Metabolism—CA2—esophageal cancer	0.000743	0.00118	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PLCE1—esophageal cancer	0.000739	0.00118	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ADH7—esophageal cancer	0.000739	0.00118	CbGpPWpGaD
Metolazone—CA5B—lung—esophageal cancer	0.000733	0.0551	CbGeAlD
Metolazone—Diarrhoea—Capecitabine—esophageal cancer	0.000731	0.00233	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000724	0.00231	CcSEcCtD
Metolazone—Insomnia—Methotrexate—esophageal cancer	0.000719	0.00229	CcSEcCtD
Metolazone—Paraesthesia—Methotrexate—esophageal cancer	0.000714	0.00227	CcSEcCtD
Metolazone—Somnolence—Methotrexate—esophageal cancer	0.000707	0.00225	CcSEcCtD
Metolazone—Dizziness—Capecitabine—esophageal cancer	0.000706	0.00225	CcSEcCtD
Metolazone—CA4—Metabolism—BLVRB—esophageal cancer	0.000705	0.00112	CbGpPWpGaD
Metolazone—CA4—Metabolism—SLC52A3—esophageal cancer	0.000705	0.00112	CbGpPWpGaD
Metolazone—CA4—trachea—esophageal cancer	0.000704	0.0529	CbGeAlD
Metolazone—Dyspepsia—Methotrexate—esophageal cancer	0.0007	0.00223	CcSEcCtD
Metolazone—Decreased appetite—Methotrexate—esophageal cancer	0.000691	0.0022	CcSEcCtD
Metolazone—CA5B—Metabolism—ADH7—esophageal cancer	0.00069	0.0011	CbGpPWpGaD
Metolazone—CA7—Metabolism—ADH7—esophageal cancer	0.00069	0.0011	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PLCE1—esophageal cancer	0.00069	0.0011	CbGpPWpGaD
Metolazone—CA7—Metabolism—PLCE1—esophageal cancer	0.00069	0.0011	CbGpPWpGaD
Metolazone—CA12—Metabolism—CA2—esophageal cancer	0.000688	0.0011	CbGpPWpGaD
Metolazone—Fatigue—Methotrexate—esophageal cancer	0.000685	0.00218	CcSEcCtD
Metolazone—Pain—Methotrexate—esophageal cancer	0.00068	0.00216	CcSEcCtD
Metolazone—Vomiting—Capecitabine—esophageal cancer	0.000679	0.00216	CcSEcCtD
Metolazone—Rash—Capecitabine—esophageal cancer	0.000673	0.00214	CcSEcCtD
Metolazone—Dermatitis—Capecitabine—esophageal cancer	0.000673	0.00214	CcSEcCtD
Metolazone—Headache—Capecitabine—esophageal cancer	0.000669	0.00213	CcSEcCtD
Metolazone—Feeling abnormal—Methotrexate—esophageal cancer	0.000655	0.00208	CcSEcCtD
Metolazone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00065	0.00207	CcSEcCtD
Metolazone—CA5A—Metabolism—ADH1B—esophageal cancer	0.000648	0.00103	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—SOD2—esophageal cancer	0.000643	0.00102	CbGpPWpGaD
Metolazone—CA12—Metabolism—ADH7—esophageal cancer	0.00064	0.00102	CbGpPWpGaD
Metolazone—CA12—Metabolism—PLCE1—esophageal cancer	0.00064	0.00102	CbGpPWpGaD
Metolazone—Nausea—Capecitabine—esophageal cancer	0.000634	0.00202	CcSEcCtD
Metolazone—Urticaria—Methotrexate—esophageal cancer	0.000632	0.00201	CcSEcCtD
Metolazone—Abdominal pain—Methotrexate—esophageal cancer	0.000629	0.002	CcSEcCtD
Metolazone—CA5A—Metabolism—TYMP—esophageal cancer	0.00062	0.000987	CbGpPWpGaD
Metolazone—CA4—digestive system—esophageal cancer	0.000606	0.0455	CbGeAlD
Metolazone—CA5B—Metabolism—ADH1B—esophageal cancer	0.000605	0.000964	CbGpPWpGaD
Metolazone—CA7—Metabolism—ADH1B—esophageal cancer	0.000605	0.000964	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CYP26A1—esophageal cancer	0.000603	0.00096	CbGpPWpGaD
Metolazone—CA4—Metabolism—CA1—esophageal cancer	0.0006	0.000955	CbGpPWpGaD
Metolazone—CA4—Metabolism—SLC10A2—esophageal cancer	0.0006	0.000955	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ALOX15—esophageal cancer	0.000587	0.000935	CbGpPWpGaD
Metolazone—Hypersensitivity—Methotrexate—esophageal cancer	0.000586	0.00186	CcSEcCtD
Metolazone—CA7—Metabolism—TYMP—esophageal cancer	0.000579	0.000921	CbGpPWpGaD
Metolazone—CA5B—Metabolism—TYMP—esophageal cancer	0.000579	0.000921	CbGpPWpGaD
Metolazone—Asthenia—Methotrexate—esophageal cancer	0.00057	0.00182	CcSEcCtD
Metolazone—CA9—Metabolism—SLC52A3—esophageal cancer	0.00057	0.000908	CbGpPWpGaD
Metolazone—CA9—Metabolism—BLVRB—esophageal cancer	0.00057	0.000908	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CYP26A1—esophageal cancer	0.000563	0.000896	CbGpPWpGaD
Metolazone—CA7—Metabolism—CYP26A1—esophageal cancer	0.000563	0.000896	CbGpPWpGaD
Metolazone—Pruritus—Methotrexate—esophageal cancer	0.000563	0.00179	CcSEcCtD
Metolazone—CA12—Metabolism—ADH1B—esophageal cancer	0.000561	0.000893	CbGpPWpGaD
Metolazone—CA5A—Metabolism—TPI1—esophageal cancer	0.00056	0.000892	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTO1—esophageal cancer	0.00056	0.000892	CbGpPWpGaD
Metolazone—CA4—Metabolism—CA2—esophageal cancer	0.000549	0.000873	CbGpPWpGaD
Metolazone—CA7—Metabolism—ALOX15—esophageal cancer	0.000548	0.000873	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ALOX15—esophageal cancer	0.000548	0.000873	CbGpPWpGaD
Metolazone—Diarrhoea—Methotrexate—esophageal cancer	0.000544	0.00173	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—HIF1A—esophageal cancer	0.00054	0.000859	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ALDOB—esophageal cancer	0.000537	0.000855	CbGpPWpGaD
Metolazone—CA12—Metabolism—TYMP—esophageal cancer	0.000536	0.000853	CbGpPWpGaD
Metolazone—Dizziness—Methotrexate—esophageal cancer	0.000526	0.00167	CcSEcCtD
Metolazone—CA5B—Metabolism—TPI1—esophageal cancer	0.000523	0.000833	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTO1—esophageal cancer	0.000523	0.000833	CbGpPWpGaD
Metolazone—CA7—Metabolism—TPI1—esophageal cancer	0.000523	0.000833	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTO1—esophageal cancer	0.000523	0.000833	CbGpPWpGaD
Metolazone—CA12—Metabolism—CYP26A1—esophageal cancer	0.000521	0.00083	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GAPDH—esophageal cancer	0.000517	0.000823	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CRABP1—esophageal cancer	0.000513	0.000816	CbGpPWpGaD
Metolazone—CA4—Metabolism—PLCE1—esophageal cancer	0.00051	0.000812	CbGpPWpGaD
Metolazone—CA4—Metabolism—ADH7—esophageal cancer	0.00051	0.000812	CbGpPWpGaD
Metolazone—CA12—Metabolism—ALOX15—esophageal cancer	0.000508	0.000809	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000507	0.000807	CbGpPWpGaD
Metolazone—CA4—lung—esophageal cancer	0.000506	0.038	CbGeAlD
Metolazone—Vomiting—Methotrexate—esophageal cancer	0.000506	0.00161	CcSEcCtD
Metolazone—CA7—Metabolism—ALDOB—esophageal cancer	0.000502	0.000799	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ALDOB—esophageal cancer	0.000502	0.000799	CbGpPWpGaD
Metolazone—CA5B—lymph node—esophageal cancer	0.000501	0.0377	CbGeAlD
Metolazone—Rash—Methotrexate—esophageal cancer	0.000501	0.0016	CcSEcCtD
Metolazone—Dermatitis—Methotrexate—esophageal cancer	0.000501	0.00159	CcSEcCtD
Metolazone—Headache—Methotrexate—esophageal cancer	0.000498	0.00159	CcSEcCtD
Metolazone—CA5A—Metabolism—GNG7—esophageal cancer	0.000488	0.000776	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000487	0.000775	CbGpPWpGaD
Metolazone—CA9—Metabolism—SLC10A2—esophageal cancer	0.000485	0.000772	CbGpPWpGaD
Metolazone—CA12—Metabolism—TPI1—esophageal cancer	0.000485	0.000772	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTO1—esophageal cancer	0.000485	0.000772	CbGpPWpGaD
Metolazone—CA9—Metabolism—CA1—esophageal cancer	0.000485	0.000772	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GAPDH—esophageal cancer	0.000483	0.000769	CbGpPWpGaD
Metolazone—CA7—Metabolism—GAPDH—esophageal cancer	0.000483	0.000769	CbGpPWpGaD
Metolazone—CA7—Metabolism—CRABP1—esophageal cancer	0.000479	0.000762	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CRABP1—esophageal cancer	0.000479	0.000762	CbGpPWpGaD
Metolazone—Nausea—Methotrexate—esophageal cancer	0.000472	0.0015	CcSEcCtD
Metolazone—CA12—Metabolism—ALDOB—esophageal cancer	0.000465	0.00074	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ALDH2—esophageal cancer	0.000457	0.000727	CbGpPWpGaD
Metolazone—CA7—Metabolism—GNG7—esophageal cancer	0.000455	0.000725	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GNG7—esophageal cancer	0.000455	0.000725	CbGpPWpGaD
Metolazone—CA12—Metabolism—GAPDH—esophageal cancer	0.000447	0.000712	CbGpPWpGaD
Metolazone—CA4—Metabolism—ADH1B—esophageal cancer	0.000447	0.000712	CbGpPWpGaD
Metolazone—CA9—Metabolism—CA2—esophageal cancer	0.000443	0.000706	CbGpPWpGaD
Metolazone—CA12—Metabolism—CRABP1—esophageal cancer	0.000443	0.000706	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CREBBP—esophageal cancer	0.000441	0.000702	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—RB1—esophageal cancer	0.000439	0.000699	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTT1—esophageal cancer	0.000435	0.000692	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CYP2A6—esophageal cancer	0.00043	0.000684	CbGpPWpGaD
Metolazone—CA4—Metabolism—TYMP—esophageal cancer	0.000427	0.00068	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ALDH2—esophageal cancer	0.000426	0.000679	CbGpPWpGaD
Metolazone—CA7—Metabolism—ALDH2—esophageal cancer	0.000426	0.000679	CbGpPWpGaD
Metolazone—CA12—Metabolism—GNG7—esophageal cancer	0.000422	0.000671	CbGpPWpGaD
Metolazone—CA4—Metabolism—CYP26A1—esophageal cancer	0.000416	0.000662	CbGpPWpGaD
Metolazone—CA9—Metabolism—PLCE1—esophageal cancer	0.000412	0.000656	CbGpPWpGaD
Metolazone—CA9—Metabolism—ADH7—esophageal cancer	0.000412	0.000656	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ENO1—esophageal cancer	0.000407	0.000648	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTGS1—esophageal cancer	0.000407	0.000648	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTT1—esophageal cancer	0.000406	0.000646	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTT1—esophageal cancer	0.000406	0.000646	CbGpPWpGaD
Metolazone—CA4—Metabolism—ALOX15—esophageal cancer	0.000405	0.000645	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PSME2—esophageal cancer	0.000401	0.000639	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PSME1—esophageal cancer	0.000401	0.000639	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CYP2A6—esophageal cancer	0.000401	0.000638	CbGpPWpGaD
Metolazone—CA7—Metabolism—CYP2A6—esophageal cancer	0.000401	0.000638	CbGpPWpGaD
Metolazone—CA12—Metabolism—ALDH2—esophageal cancer	0.000395	0.000629	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTO1—esophageal cancer	0.000387	0.000615	CbGpPWpGaD
Metolazone—CA4—Metabolism—TPI1—esophageal cancer	0.000387	0.000615	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CDKN2A—esophageal cancer	0.000386	0.000615	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTGS1—esophageal cancer	0.00038	0.000605	CbGpPWpGaD
Metolazone—CA7—Metabolism—ENO1—esophageal cancer	0.00038	0.000605	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTGS1—esophageal cancer	0.00038	0.000605	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ENO1—esophageal cancer	0.00038	0.000605	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTT1—esophageal cancer	0.000376	0.000598	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PSME1—esophageal cancer	0.000375	0.000596	CbGpPWpGaD
Metolazone—CA7—Metabolism—PSME2—esophageal cancer	0.000375	0.000596	CbGpPWpGaD
Metolazone—CA7—Metabolism—PSME1—esophageal cancer	0.000375	0.000596	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PSME2—esophageal cancer	0.000375	0.000596	CbGpPWpGaD
Metolazone—CA12—Metabolism—CYP2A6—esophageal cancer	0.000371	0.000591	CbGpPWpGaD
Metolazone—CA4—Metabolism—ALDOB—esophageal cancer	0.000371	0.00059	CbGpPWpGaD
Metolazone—CA9—Metabolism—ADH1B—esophageal cancer	0.000361	0.000575	CbGpPWpGaD
Metolazone—CA4—Metabolism—GAPDH—esophageal cancer	0.000357	0.000568	CbGpPWpGaD
Metolazone—CA4—Metabolism—CRABP1—esophageal cancer	0.000354	0.000563	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTGS1—esophageal cancer	0.000352	0.000561	CbGpPWpGaD
Metolazone—CA12—Metabolism—ENO1—esophageal cancer	0.000352	0.000561	CbGpPWpGaD
Metolazone—CA12—Metabolism—PSME2—esophageal cancer	0.000347	0.000552	CbGpPWpGaD
Metolazone—CA12—Metabolism—PSME1—esophageal cancer	0.000347	0.000552	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CYP1B1—esophageal cancer	0.000346	0.000551	CbGpPWpGaD
Metolazone—CA4—lymph node—esophageal cancer	0.000346	0.026	CbGeAlD
Metolazone—CA9—Metabolism—TYMP—esophageal cancer	0.000345	0.00055	CbGpPWpGaD
Metolazone—CA4—Metabolism—GNG7—esophageal cancer	0.000336	0.000535	CbGpPWpGaD
Metolazone—CA9—Metabolism—CYP26A1—esophageal cancer	0.000336	0.000535	CbGpPWpGaD
Metolazone—CA9—Metabolism—ALOX15—esophageal cancer	0.000327	0.000521	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CYP19A1—esophageal cancer	0.000326	0.000518	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000325	0.000518	CbGpPWpGaD
Metolazone—CA7—Metabolism—CYP1B1—esophageal cancer	0.000323	0.000515	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CYP1B1—esophageal cancer	0.000323	0.000515	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CDKN1A—esophageal cancer	0.000315	0.000502	CbGpPWpGaD
Metolazone—CA4—Metabolism—ALDH2—esophageal cancer	0.000315	0.000502	CbGpPWpGaD
Metolazone—CA9—Metabolism—TPI1—esophageal cancer	0.000312	0.000497	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTO1—esophageal cancer	0.000312	0.000497	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CYP19A1—esophageal cancer	0.000304	0.000484	CbGpPWpGaD
Metolazone—CA7—Metabolism—CYP19A1—esophageal cancer	0.000304	0.000484	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—EP300—esophageal cancer	0.0003	0.000478	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTT1—esophageal cancer	0.0003	0.000477	CbGpPWpGaD
Metolazone—CA12—Metabolism—CYP1B1—esophageal cancer	0.000299	0.000477	CbGpPWpGaD
Metolazone—CA9—Metabolism—ALDOB—esophageal cancer	0.000299	0.000477	CbGpPWpGaD
Metolazone—CA5A—Metabolism—HMOX1—esophageal cancer	0.000297	0.000473	CbGpPWpGaD
Metolazone—CA4—Metabolism—CYP2A6—esophageal cancer	0.000296	0.000472	CbGpPWpGaD
Metolazone—CA9—Metabolism—GAPDH—esophageal cancer	0.000288	0.000459	CbGpPWpGaD
Metolazone—CA9—Metabolism—CRABP1—esophageal cancer	0.000286	0.000455	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ABCB1—esophageal cancer	0.000285	0.000454	CbGpPWpGaD
Metolazone—CA12—Metabolism—CYP19A1—esophageal cancer	0.000282	0.000448	CbGpPWpGaD
Metolazone—CA4—Metabolism—ENO1—esophageal cancer	0.000281	0.000447	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTGS1—esophageal cancer	0.000281	0.000447	CbGpPWpGaD
Metolazone—CA7—Metabolism—HMOX1—esophageal cancer	0.000277	0.000442	CbGpPWpGaD
Metolazone—CA5B—Metabolism—HMOX1—esophageal cancer	0.000277	0.000442	CbGpPWpGaD
Metolazone—CA4—Metabolism—PSME1—esophageal cancer	0.000277	0.000441	CbGpPWpGaD
Metolazone—CA4—Metabolism—PSME2—esophageal cancer	0.000277	0.000441	CbGpPWpGaD
Metolazone—CA9—Metabolism—GNG7—esophageal cancer	0.000272	0.000433	CbGpPWpGaD
Metolazone—CA7—Metabolism—ABCB1—esophageal cancer	0.000266	0.000424	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ABCB1—esophageal cancer	0.000266	0.000424	CbGpPWpGaD
Metolazone—CA12—Metabolism—HMOX1—esophageal cancer	0.000257	0.000409	CbGpPWpGaD
Metolazone—CA9—Metabolism—ALDH2—esophageal cancer	0.000255	0.000405	CbGpPWpGaD
Metolazone—CA12—Metabolism—ABCB1—esophageal cancer	0.000247	0.000393	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTT1—esophageal cancer	0.000242	0.000386	CbGpPWpGaD
Metolazone—CA9—Metabolism—CYP2A6—esophageal cancer	0.000239	0.000381	CbGpPWpGaD
Metolazone—CA4—Metabolism—CYP1B1—esophageal cancer	0.000239	0.00038	CbGpPWpGaD
Metolazone—CA9—Metabolism—ENO1—esophageal cancer	0.000227	0.000361	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTGS1—esophageal cancer	0.000227	0.000361	CbGpPWpGaD
Metolazone—CA4—Metabolism—CYP19A1—esophageal cancer	0.000225	0.000357	CbGpPWpGaD
Metolazone—CA9—Metabolism—PSME2—esophageal cancer	0.000224	0.000356	CbGpPWpGaD
Metolazone—CA9—Metabolism—PSME1—esophageal cancer	0.000224	0.000356	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TP53—esophageal cancer	0.000215	0.000342	CbGpPWpGaD
Metolazone—CA4—Metabolism—HMOX1—esophageal cancer	0.000205	0.000326	CbGpPWpGaD
Metolazone—CA4—Metabolism—ABCB1—esophageal cancer	0.000197	0.000313	CbGpPWpGaD
Metolazone—CA9—Metabolism—CYP1B1—esophageal cancer	0.000193	0.000307	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CREBBP—esophageal cancer	0.000191	0.000303	CbGpPWpGaD
Metolazone—CA9—Metabolism—CYP19A1—esophageal cancer	0.000181	0.000289	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CREBBP—esophageal cancer	0.000178	0.000283	CbGpPWpGaD
Metolazone—CA7—Metabolism—CREBBP—esophageal cancer	0.000178	0.000283	CbGpPWpGaD
Metolazone—CA5A—Metabolism—NOS3—esophageal cancer	0.000171	0.000272	CbGpPWpGaD
Metolazone—CA9—Metabolism—HMOX1—esophageal cancer	0.000166	0.000264	CbGpPWpGaD
Metolazone—CA12—Metabolism—CREBBP—esophageal cancer	0.000165	0.000262	CbGpPWpGaD
Metolazone—CA7—Metabolism—NOS3—esophageal cancer	0.000159	0.000254	CbGpPWpGaD
Metolazone—CA5B—Metabolism—NOS3—esophageal cancer	0.000159	0.000254	CbGpPWpGaD
Metolazone—CA9—Metabolism—ABCB1—esophageal cancer	0.000159	0.000253	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTGS2—esophageal cancer	0.000156	0.000248	CbGpPWpGaD
Metolazone—CA12—Metabolism—NOS3—esophageal cancer	0.000148	0.000235	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTGS2—esophageal cancer	0.000146	0.000232	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTGS2—esophageal cancer	0.000146	0.000232	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTGS2—esophageal cancer	0.000135	0.000215	CbGpPWpGaD
Metolazone—CA4—Metabolism—CREBBP—esophageal cancer	0.000131	0.000209	CbGpPWpGaD
Metolazone—CA5A—Metabolism—EP300—esophageal cancer	0.00013	0.000207	CbGpPWpGaD
Metolazone—CA7—Metabolism—EP300—esophageal cancer	0.000121	0.000193	CbGpPWpGaD
Metolazone—CA5B—Metabolism—EP300—esophageal cancer	0.000121	0.000193	CbGpPWpGaD
Metolazone—CA4—Metabolism—NOS3—esophageal cancer	0.000118	0.000187	CbGpPWpGaD
Metolazone—CA12—Metabolism—EP300—esophageal cancer	0.000112	0.000179	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTGS2—esophageal cancer	0.000108	0.000171	CbGpPWpGaD
Metolazone—CA9—Metabolism—CREBBP—esophageal cancer	0.000106	0.000169	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PIK3CA—esophageal cancer	9.6e-05	0.000153	CbGpPWpGaD
Metolazone—CA9—Metabolism—NOS3—esophageal cancer	9.51e-05	0.000151	CbGpPWpGaD
Metolazone—CA7—Metabolism—PIK3CA—esophageal cancer	8.96e-05	0.000143	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PIK3CA—esophageal cancer	8.96e-05	0.000143	CbGpPWpGaD
Metolazone—CA4—Metabolism—EP300—esophageal cancer	8.95e-05	0.000143	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTGS2—esophageal cancer	8.7e-05	0.000138	CbGpPWpGaD
Metolazone—CA12—Metabolism—PIK3CA—esophageal cancer	8.3e-05	0.000132	CbGpPWpGaD
Metolazone—CA9—Metabolism—EP300—esophageal cancer	7.23e-05	0.000115	CbGpPWpGaD
Metolazone—CA4—Metabolism—PIK3CA—esophageal cancer	6.62e-05	0.000105	CbGpPWpGaD
Metolazone—CA9—Metabolism—PIK3CA—esophageal cancer	5.35e-05	8.52e-05	CbGpPWpGaD
